HARMONY BIOSCIENCES HOLDINGS, INC. Shareholders' Equity
HARMONY BIOSCIENCES HOLDINGS, INC. (HRMY) had Shareholders' Equity of $999.24 million as of 2026-06-30, per its 10-Q filed 2026-08-04.
Financial Statements › Balance Sheet › Equity › Equity, Attributable to Parent
us-gaap:StockholdersEquity · last filed 2026-08-04
- 2026-06-30: Stockholders' Equity Attributable to Parent $999.24M.
- 2026-03-31: Stockholders' Equity Attributable to Parent $910.35M.
- 2025-12-31: Stockholders' Equity Attributable to Parent $870.22M.
- 2025-09-30: Stockholders' Equity Attributable to Parent $835.12M.
| Period end | Stockholders' Equity Attributable to Parent |
|---|---|
| 2026-06-30 | $999.24M 10-Q · filed 2026-08-04 |
| 2026-03-31 | $910.35M 10-Q · filed 2026-08-04 |
| 2025-12-31 | $870.22M 10-Q · filed 2026-08-04 |
| 2025-09-30 | $835.12M 10-Q · filed 2025-11-04 |
| 2025-06-30 | $773.08M 10-Q · filed 2026-08-04 |
| 2025-03-31 | $720.52M 10-Q · filed 2026-08-04 |
| 2024-12-31 | $659.15M 10-Q · filed 2026-08-04 |
| 2024-09-30 | $596.80M 10-Q · filed 2025-11-04 |
| 2024-06-30 | $538.58M 10-Q · filed 2025-11-04 |
| 2024-03-31 | $515.39M 10-Q · filed 2025-08-05 |
| 2023-12-31 | $466.99M 10-K · filed 2026-02-24 |
| 2023-09-30 | $481.33M 10-Q · filed 2024-10-29 |
| 2023-06-30 | $485.17M 10-Q · filed 2024-10-29 |
| 2023-03-31 | $443.04M 10-Q · filed 2024-08-06 |
| 2022-12-31 | $402.84M 10-K · filed 2026-02-24 |
| 2022-09-30 | $343.88M 10-Q · filed 2023-10-31 |
| 2022-06-30 | $246.53M 10-Q · filed 2023-10-31 |
| 2022-03-31 | $214.50M 10-Q · filed 2023-08-01 |
| 2021-12-31 | $186.51M 10-K · filed 2025-02-25 |
| 2021-09-30 | $152.02M 10-Q · filed 2022-11-01 |
| 2021-06-30 | $126.55M 10-Q · filed 2022-11-01 |
| 2021-03-31 | $107.88M 10-Q · filed 2022-08-02 |
| 2020-12-31 | $97.18M 10-K · filed 2024-02-22 |
| 2020-09-30 | $94.55M 10-Q · filed 2021-11-09 |
| 2020-06-30 | -$483.36M 10-Q · filed 2021-11-09 |
| 2020-03-31 | -$472.33M 10-Q · filed 2021-08-10 |
| 2019-12-31 | -$422.86M 10-K · filed 2023-02-21 |
| 2019-09-30 | -$384.91M 10-Q · filed 2020-11-12 |
| 2019-06-30 | -$343.63M 10-Q · filed 2020-11-12 |
| 2018-12-31 | -$242.67M 10-K · filed 2022-02-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Vera Therapeutics, Inc. (VERA) | United States | $2.402B | -7.67 |
| uniQure N.V. (QURE) | $2.416B | -4.93 | |
| SELLAS Life Sciences Group, Inc. (SLS) | United States | $2.420B | -91.87 |
| Mineralys Therapeutics, Inc. (MLYS) | United States | $2.353B | -6.82 |
| Viridian Therapeutics, Inc.\DE (VRDN) | United States | $2.342B | -5.38 |
| Nurix Therapeutics, Inc. (NRIX) | United States | $2.457B | -5.39 |
| SUPERNUS PHARMACEUTICALS, INC. (SUPN) | United States | $2.517B | -24.63 |
| Immunome Inc. (IMNM) | United States | $2.538B | -9.45 |
| Disc Medicine, Inc. (IRON) | United States | $2.553B | -11.40 |
| Zai Lab Ltd (ZLAB) | $2.241B | -113.34 |